NCT06655129

Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder

Post Market Clinical Study of an Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 85 (estimated)
• Sponsor: Eurofeedback · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders: * Excessive Hairiness (Hirsutism, Hypertrichosis...) * Vascular lesions (Rosacea….) * Pigmented lesions (Lentigo et melasma) * Acne vulgaris

Conditions

• Excessive Hairiness
• Vascular Lesion
• Pigmented Lesions
• Acne Vulgaris

Interventions

Type	Name	Description
DEVICE	intense pulsed light	intense pulsed light (IPL) using the Medical Device Anthelia

Timeline

• Start date: 2024-01-20
• Primary completion: 2024-12-30
• Completion: 2025-12-01
• First posted: 2024-10-23
• Last updated: 2024-10-23

Locations

5 sites across 1 country: France